Grail CEO Robert Ragusa sells $237,976 in stock

Published 12/03/2025, 21:12
Grail CEO Robert Ragusa sells $237,976 in stock

In a recent transaction, Robert Ragusa, Chief Executive Officer of GRAIL, Inc. (NASDAQ:GRAL), sold 7,625 shares of the company’s common stock. The timing of this sale comes as GRAL’s stock has experienced a significant -20% decline over the past week, despite posting impressive gains of over 125% in the past six months. The shares were sold at a weighted average price of $31.21 per share, amounting to a total transaction value of approximately $237,976. Following this sale, Ragusa retains ownership of 828,662 shares in the company. The sale was executed as part of a block trade involving multiple transactions. According to InvestingPro analysis, GRAL maintains strong liquidity with a current ratio of 10.66, though the company is currently experiencing rapid cash burn. Get access to 12 additional key ProTips and comprehensive analysis in the Pro Research Report, available exclusively on InvestingPro.

In other recent news, Grail Inc. reported a 26% increase in revenue for the fourth quarter of 2024, totaling $38.3 million. Despite a net loss of $97.1 million, the company improved its financial standing by reducing its quarterly loss by 48%. The company’s annual revenue for 2024 reached $125.6 million, marking a 35% rise from the previous year, driven primarily by a 45% increase in screening revenue from the sale of 137,000 Galleri tests. Additionally, Grail launched an enhanced version of its Galleri test, which is designed for scalability and cost efficiency. The company maintained its 2025 guidance and anticipates a reduction in cash burn by over 40% in the coming year. Grail plans to complete its registrational studies and submit a modular PMA to the FDA by the first half of 2026. The U.S. Military’s TRICARE health insurance program has also added the Galleri test to its list of approved lab-developed tests for patients over 50 with elevated cancer risk. These developments reflect Grail’s strategic initiatives and progress in the cancer detection market.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.